Introduction
Specific protein inclusions and/or aggregates define most neurodegenerative diseases at the pathological level. In Alzheimer's disease, beyond the abnormal aggregation of amyloid-b peptide and hyperphosphorylated tau proteins, the pathology has a chronic neuroinflammatory component that involves activation of microglia and astrocytes (Heneka et al., 2015) . Misfolded and aggregated proteins bind to pattern recognition receptors expressed by microglia and astroglia, and trigger an innate immune response characterized by the release of inflammatory mediators and/or clearance of pathological proteins. Although accumulating evidence indicate that such chronic neuroinflammatory responses play an instrumental role in the disease pathophysiology, it remains unclear whether they are protective, damaging or both depending on disease stages.
A marked accumulation and activation of microglia around amyloid-b plaques has been described in postmortem brains of patients with Alzheimer's disease and in animal models of Alzheimer's disease-like pathology (Prokop et al., 2013) . One pathophysiological model proposes that microglia are attracted towards amyloid-b deposits, which they internalize and degrade, thus playing a protective role by promoting clearance of amyloid-b from the brain. In later disease stages, microglia may lose this beneficial effect and acquire a 'toxic' phenotype as a consequence of chronic activation and continued production of proinflammatory mediators, in a process that may occur independently of amyloid pathology (Prokop et al., 2013; Michaud and Rivest, 2015) .
In humans, brain neuroinflammation has been investigated using PET imaging of the 18-kDa translocator protein (TSPO) (Kreisl et al., 2013) , which is considered as a marker of microglial activation. However, the studies using the first ( 11 C-PK11195) or the second generation of TSPO radiotracers showed somewhat contradictory results (Lagarde et al., 2017) . Varying extents and levels of microglial activation have been identified in prodromal Alzheimer's disease (Okello et al., 2009; Wiley et al., 2009; Kreisl et al., 2013; Fan et al., 2015a; Hamelin et al., 2016) . A relationship was reported between microglial activation and cortical amyloid load (Hamelin et al., 2016; Parbo et al., 2017) , but a recent publication including patients with typical and atypical Alzheimer's disease showed that microglial activation is closely associated with markers of neurodegeneration, suggesting a potential interplay with tau pathology (Kreisl et al., 2017) . In addition, no difference in 18 F-DPA-714 binding was found between early and late onset of Alzheimer's disease in a larger sample of patients (Hamelin et al., 2016) . Finally, only few studies investigated the predictive value of microglial activation in Alzheimer's disease progression, and our previous work suggested an early protective role in the largest cohort to date (Hamelin et al., 2016) . Only three longitudinal studies of microglial activation in Alzheimer's disease have been reported up to now, the interpretation of which must be taken cautiously due to small sample sizes. Two studies using 11 C-PK11195 (Fan et al., 2015b (Fan et al., , 2017 showed a surprising reduction of microglial activation in eight patients with mild cognitive impairment with different amyloidosis status, whereas increased 11 C-PK11195 binding was reported in the eight patients with Alzheimer's disease included. Using 11 C-PBR28, a mild increase of TSPO binding in 14 patients with Alzheimer's disease was found associated with clinical worsening (Kreisl et al., 2016) .
In light of these results, the spectrum of microglial activation patterns and their impact on disease progression in Alzheimer's disease remain controversial.
The present work aimed at first evaluating the predictive value of microglial activation assessed by 18 F-DPA-714 PET imaging in a large cohort of patients with Alzheimer's disease, based on functional, cognitive and MRI biomarkers outcomes after a 2-year follow-up. Second, in the same cohort we aimed at investigating the longitudinal progression of 18 F-DPA-714 binding in patients with Alzheimer's disease by comparison with controls, and assess its influence on clinical progression.
Materials and methods

Study design and participants
All participants were enrolled in the prospective longitudinal IMABio3 study (NCT01775696), which aimed at assessing the brain neuroinflammatory response in Alzheimer's disease. The study was approved by a French Ethical Committee. All subjects provided written informed consent prior to participating.
Patients with Alzheimer's disease were included according to the following criteria: (i) progressive episodic memory impairment, characterized by a low free recall not normalized with semantic cueing (Sarazin et al., 2007; Dubois et al., 2010) ; (ii) absence of extrapyramidal signs; (iii) positive pathophysiological markers of Alzheimer's disease, defined by CSF Alzheimer's disease profile {score 5 0.8, calculated with the formula amyloid-b 42 /[240 + (1.18 T-tau)]} (de Souza et al., 2011) and amyloid Pittsburgh compound B (PiB)-PET imaging [global cortical index (GCI) 4 1.45]. These conservative thresholds were used to ensure the pathophysiological diagnosis of Alzheimer's disease. Patients with Alzheimer's disease were defined as prodromal Alzheimer's disease when their Clinical Dementia Rating (CDR) score was 0.5, and as demented-Alzheimer's disease when their CDR score was 51.
Controls were recruited according to the following criteria: (i) Mini-Mental State Examination (MMSE) score 5 27/30 and normal neuropsychological assessment; (ii) CDR = 0; (iii) no history of neurological or psychiatric disorders; (iv) no memory complaint or cognitive deficit, and (v) negative amyloid PiB-PET imaging (GCI 5 1.4). Controls with a positive amyloid PiB-PET imaging (GCI 4 1.45) were defined as amyloidosis-positive controls and analysed separately.
We did not include subjects with (i) severe cortical or subcortical vascular lesions; (ii) history of autoimmune and inflammatory diseases or chronic migraines; (iii) history of psychiatric disorders; or (iv) suspicion of alcohol or drugs abuse. No subject was treated with corticoid or non-steroidal anti-inflammatory drug (NSAID) or benzodiazepine, known to interfere with TSPO.
Blood samples were drawn to characterize APOE and TSPO genotypes (Hamelin et al., 2016) . Based on the rs6971 polymorphism within the TSPO gene, we classified all subjects into three groups: high affinity binders, mixed affinity binders or low affinity binders.
At baseline, all participants underwent the same procedure including a complete clinical and neuropsychological assessment, 3 T brain MRI, 11 C-PiB and 18 F-DPA-714 PET imaging (called DPA-1). Participants were then followed up annually with repeated standardized clinical and neuropsychological assessments and 3 T brain MRI, for 2 years. The last year of the study, subjects were asked to undergo a second 18 F-DPA-714 PET imaging (called DPA-2), respecting a minimum of 12 months delay after DPA-1 for patients with Alzheimer's disease and 24 months delay for controls.
Among the 73 patients with Alzheimer's disease who fulfilled all inclusion criteria, initial DPA-1 PET scan could not be carried out for seven patients because of technical reasons. Eight patients were withdrawn during the 2-year follow-up period (one intercurrent disease, two nursing home, three lost to follow-up, two deaths). Finally, 58 patients with Alzheimer's disease (including six low affinity binders) with DPA-1 completed the 2-year clinical follow-up. Twenty-seven patients with Alzheimer's disease underwent a second 18 F-DPA-714 PET imaging (n = 18 refused to perform it, n = 3 were at a severe dementia stage making it impossible to carry out a PET acquisition; n = 10 were outside the regulatory limits of the study). PET acquisition failed for technical reasons for three of them. Finally, 24 patients with Alzheimer's disease (18 prodromal Alzheimer's disease and six demented Alzheimer's disease), including three low affinity binders had both DPA-1 and DPA-2 PET scans. The mean delay between DPA-1 and DPA-2 was 1.57 AE 0.3 years.
Twenty-nine controls with DPA-1 completed the 2-year clinical follow-up. Among them, eight controls were defined as amyloidosis-positive and analysed separately. A second 18 F-DPA-714 PET scan was performed for 15/21 amyloidosis negative controls (n = 3 were outside the regulatory time limit; n = 3 refused DPA-2 PET scan) and 6/8 amyloidosis positive controls (n = 2 refused to perform DPA-2 PET scan). The mean delay between DPA-1 and DPA-2 in controls was 2.2 AE 0.2 years.
Clinical, functional and cognitive assessment
Standardized neurological and neuropsychological examination was performed annually for 2 years, including the MMSE, CDR scale, Montgomery-Asberg Depression Scale (MADRS) and a standardized cognitive battery for assessing verbal and visual episodic memory, executive functions, gesture praxis, visuo-constructive functions and language. Record of medical events and current treatment were also reported.
Definitions of slow and fast decliners
After 2 years of follow-up, we used two complementary clinical outcomes to define slow (SD) and fast decliners (FD). The functional (fn) progression was assessed on the basis of the CDR change: patients with Alzheimer's disease were classified as functional slow decliners when CDR was unchanged and as functional fast decliners when CDR increased. The cognitive (co) progression was assessed by the MMSE score decline over time (cognitive slow decliners: ÁMMSE score 4 4 points; cognitive fast decliners: ÁMMSE 4 4 points). The cut-off value of 4 points was determined according to knowledge based on longitudinal studies, which have shown that the minimal mean annual rate of progression of cognitive impairment was $1-2 points when assessed with the MMSE (Kinkingnéhun et al., 2008) . Of note, MMSE scores at the last visit were missing for three patients with Alzheimer's disease because of too severe cognitive decline.
MRI acquisition and hippocampal volume measurements
Each participant underwent a MRI examination annually during 2 years, using the same scanner at all visits for reducing equipment-related variability. 3D T 1 -weighted structural MRI acquisitions were obtained on a 3 T MRI scanner (Siemens Trio, 32 channel system, with a 12-channel head coil for signal reception). This sequence provided a high grey/white matter contrast-to-noise ratio and enabled excellent segmentation and accurate co-registration with PET images (Hamelin et al., 2016) . Segmentation of the hippocampus was carried out using an automated method (Chupin et al., 2009) . For measuring hippocampal atrophy progression and increase the sensitivity to actual change, the two MRI time points were computed together as previously described (Dubois et al., 2015) . Hippocampal volumes were adjusted for head size by correcting for total intracranial volume, derived from SPM8 segmentations. We calculated the percentage of left and right hippocampal volume loss as well as the mean of left + right hippocampal volume loss after 2 years of follow-up.
C-PiB and
18 F-DPA-714 PET imaging procedure Data acquisition MRI and PET scans were performed within 4 months of each other. At baseline, 11 C-PiB and 18 F-DPA-714 PET scans were performed on the same day. All PET scans were performed using the same camera: a High Resolution Research Tomograph (HRRT; CTI/Siemens Molecular Imaging) (de Jong et al., 2007) . A 6-min brain transmission scan was performed before injection of each radioligand using a 137 Cs point source to correct the emission scan for tissue attenuation.
11 C-PiB-PET (362 AE 45 MBq) and 18 F-DPA-714 PET (DPA-1: 197 AE 17 MBq and DPA-2: 197 AE 12 MBq) were injected intravenously, and PET dynamic acquisitions in list mode lasted up to 90 min. All corrections (attenuation, normalization, random and scatter coincidences) were incorporated in an iterative OSEM reconstruction. The partial volume effect was corrected by directly incorporating resolution modelling (i.e. Point Spread Function modelling) inside the iterative algorithm (Sureau et al., 2008) so that no further post-correction was needed. Ten iterations using 16 subsets were used. Dynamic data were binned into 27 time frames (6 Â 1 min, 7 Â 2 min, 14 Â 5 min). Reconstructed dynamic data were realigned for motion correction according to the process of frame-to-reference image registration in Pmod (version 3.5; PMOD Technologies Ltd.).
Parametric images were created using Brainvisa software (http://brainvisa.info). Standard uptake value (SUV) parametric images were obtained by: (i) averaging late images (intervals of 40-60 min for 11 C-PiB and of 60-90 min for 18 F-DPA-714) (Lopresti et al., 2005; Lavisse et al., 2015) ; and (ii) adjusting for body weight and injected radioligand dose. The cerebellar grey matter was used as a pseudo reference region in both 11 C-PiB and 18 F-DPA-714 PET analyses to obtain a SUVr (de Souza et al., 2011; Hamelin et al., 2016) .
Volume of interest analysis
The same method of anatomical segmentation was used for both 11 C-PiB and 18 F-DPA-714 PET images, as described previously (Hamelin et al., 2016) . Briefly, an automated segmentation of grey matter was performed to each individual 3D T 1 -weighted MRI scan using the VBM8 package (http://dbm. neuro.uni-jena.de/vbm/) implemented in SPM8 (Institute of Neurology, London, UK; http://www.fil.ion.ucl.ac.uk/spm/). The segmented MRI scans were co-registered with both 11 C-PiB and 18 F-DPA-714 parametric images of the subject using a standard mutual information algorithm. The automated anatomical labelling (AAL) atlas was normalized to each individual MRI (using the deformation field extracted from VBM8). Each volume of interest was intersected with the T 1 MRI grey matter mask to perform a pseudo-atrophy correction. Then, this new labelling volume was registered to the individual PET space of 11 C-PiB and 18 F-DPA-714 parametric images using their respective transformation extracted from the PET-MRI co-registration. Similarly, cerebellar grey matter was identified for each subject, eroded (4 mm), and used as a pseudo-reference region.
Application of the AAL atlas to the PET data allowed the calculation of 11 C-PiB and 18 F-DPA-714 uptake in 76 anatomical regions. The volumes of interest were defined separately for the left and right hemispheres and were then pooled into greater anatomical volumes of interest, as previously described (de Souza et al., 2011) . Briefly, we defined eight volumes of interest: (i) the frontal cortex; (ii) anterior cingulate; (iii) medium cingulate; (iv) posterior cingulate; (v) precuneus; (vi) parietal cortex; (vii) temporal cortex; and (viii) posterior cortex. A mean 11 C-PiB and 18 F-DPA-714 SUVr were obtained for each region. As a measure of global cortical burden, we calculated a 11 C-PiB and 18 F-DPA-714 GCI, representing the subject's mean SUVr of the neocortical regions cited above (de Souza et al., 2011; Hamelin et al., 2016) .
Voxel-wise analysis
We used SPM8, implemented on a MATLAB platform (Mathworks Inc.). All PET images were spatially normalized onto the standard Montreal Neurological Institute (MNI) and were smoothed with an 8 mm full-width at half-maximum Gaussian filter.
In the DPA-PET predictive analysis, we used unpaired t-test comparisons with age, TSPO genotype and MMSE score as covariates to compare fast and slow decliners (P 5 0.001 uncorrected).
In the DPA-PET longitudinal study, we used an unpaired two-sample t-test with TSPO genotype and interval time between the two PET acquisitions as covariates for comparing Alzheimer's disease and control groups. The threshold was set at P 5 0.001 uncorrected. In addition, evolution of DPA-714 binding in subjects was assessed by using the percentage of DPA changes per year, calculated individually at the voxel level in the MNI space, as follows:
Where DPA-1 and DPA-2 are DPA-714 SUVr at baseline and follow-up, respectively, and Át the time interval between the two DPA-714 PET scans.
Voxels of percentage were then compared between groups using unpaired t-test with age, TSPO genotype and initial MMSE score as covariates. Correlation analyses used multiple regression design, and TSPO genotype, age and initial MMSE score were included as covariates. For all analyses, a minimum-activated voxel threshold of 20 voxels was applied.
Statistical analysis
In accordance with recent reports, we pooled the mixed affinity and high affinity binders together and used the TSPO genotype as a covariate in all statistical analyses. In the DPA-PET predictive analysis, we excluded 6/58 low affinity binders with Alzheimer's disease. The analysis of the DPA-PET longitudinal study was similarly carried out without including low affinity binders. However, as the low affinity binders could be considered as their own controls longitudinally, we verified that our results were not changed when including low affinity binders.
Data were analysed using SPSS20 (SPSS Inc., Chicago, Illinois), STATISTICA 6 software (Statsoft) and R, a software environment for statistical computing and graphics (http:// www.R-project.org/). Normality of distribution was tested using the Shapiro-Wilk test. Differences between groups were assessed using 2 -test, ANOVA, or Kruskall-Wallis tests when appropriate.
ANCOVA, adjusted for age, TSPO genotype and initial MMSE score was used for comparing 18 F-DPA-714 binding between groups at baseline (DPA-1). For follow-up comparisons and comparisons of percentage of change, the interval time between both 18 F-DPA-714 scans was also added as a covariate (see methodological considerations below for more details).
We used one-tailed linear partial correlation analyses with age, TSPO genotype and initial MMSE score as covariates. We used one-tailed tests as the correlation analyses followed comparisons between groups, which gave us a hypothesis regarding the direction of the correlation.
Results
For clarity, the term 'DPA-PET predictive analysis' will refer to assessing how initial microglial activation (DPA-1) is associated with the rapidity of Alzheimer's disease progression after 2 years of clinical follow-up. The term 'DPA-PET longitudinal analysis' will refer to analysing the dynamic profile of microglial activation (DPA-2 versus DPA-1) in patients with Alzheimer's disease as compared to controls, and its relationship with Alzheimer's disease clinical progression.
DPA-PET predictive analysis Population description
Fifty-two patients with Alzheimer's disease (33 at the prodromal stage and 19 at the dementia stage) and 17 controls were studied (after excluding low affinity binders) ( Table 1) . There was no significant difference in terms of age or educational level between Alzheimer's disease and control groups. The prevalence of APOE E4 carriers was higher among patients with Alzheimer's disease. Detailed neuropsychological evaluations of prodromal and dementia Alzheimer's disease subgroups are summarized in Supplementary Table 1 . Treatments were comparable in the prodromal-Alzheimer's disease and dementedAlzheimer's disease subgroups, except for the use of memantine, which was more frequent in demented patients (6/19). There was no change in treatment for Alzheimer's disease during follow-up. Patients with Alzheimer's disease exhibited a smaller hippocampal volume at baseline and a higher progression of hippocampal atrophy than controls. After 2 years of follow-up, 17 patients with Alzheimer's disease had unchanged CDR score and were defined as functional slow decliners and 35 had an increased CDR score and were defined as functional fast decliners. Considering the loss of MMSE scores, 23 patients with Alzheimer's disease were considered as cognitive slow decliners (mean loss of MMSE = 0.9 AE 2.2) and 26 as cognitive fast decliners (mean loss of MMSE = 8.2 AE 3.2). Detailed rates of decline of the neuropsychological variables in the fast and slow decliners groups over 2 years are shown in Supplementary Table 2 . At baseline, functional slow and functional fast decliners as well as cognitive slow and cognitive fast decliners did not differ in terms of educational level, disease duration and baseline neuropsychological variables, but differed in age and MMSE score (fast decliners were younger and had a lower MMSE score). Consequently, age and MMSE scores were systematically used as covariates in all subsequent analyses.
18 F-DPA-714 cortical binding at baseline (DPA-1)
Volume of interest analysis
We first compared the whole Alzheimer's disease cohort to controls. DPA-1 binding was significantly higher in patients with Alzheimer's disease as compared to controls, especially in the temporal and parietal regions (Supplementary Table 3 ). No significant difference of DPA-1 binding was found between prodromal Alzheimer's disease and dementia Alzheimer's disease subjects. There was a positive correlation between the DPA-1 GCI and the baseline MMSE score (r = 0.26, P = 0.037), left hippocampal volume (r = 0.31, P = 0.04) and cortical volume (r = 0.25, P = 0.04), with TSPO genotype, age and CDR as covariates. Because young patients with Alzheimer's disease had a faster clinical progression over time, we verified that no 18 F-DPA-714 uptake difference was observed between patients with early and late onset of Alzheimer's disease. In addition, we did not find any correlation between age and initial 18 F-DPA-714 uptake.
Then we compared the DPA-1 binding between slow and fast decliners. DPA-1 binding was significantly higher in functional slow decliners than in functional fast decliners in all cortical regions as well as for the global index (P = 0.001; with age, TSPO genotype and initial MMSE score as covariates) (Table 1 and Fig. 1A ). Similar results were observed when comparing DPA-1 between cognitive slow and cognitive fast decliners, although with lower statistical power (GCI: P = 0.04, Table 1 ).
Finally, we compared DPA-1 binding in slow and fast decliners within the subgroups of patients at either prodromal stage (CDR = 0.5 at inclusion) or dementia stage (CDR 5 1 at baseline) separately. Regarding the prodromal patients with Alzheimer's disease, DPA-1 binding was significantly higher in functional slow decliners (n = 11) than in functional fast decliners (n = 22), especially in the anterior regions, as well as in cognitive slow decliners (n = 15) than in cognitive fast decliners (n = 18) (Fig. 1) . Concerning the demented patients with Alzheimer's disease, we also found higher DPA-1 binding in the functional slow decliners (n = 6) than in the functional fast decliners (n = 13), but no significant difference was observed between cognitive slow (n = 8) and cognitive fast decliners (n = 8), taking into account that MMSE scores were lacking at the last visit for three patients with Alzheimer's disease because of too severe cognitive impairment.
Voxel-wise comparisons
The voxel-wise analysis showed a higher 18 F-DPA-714 binding in functional slow decliners when compared to functional fast decliners (P 5 0.001, uncorrected; with age, TSPO and MMSE as covariates), which is more pronounced in the anterior regions in prodromal patients with Alzheimer's disease ( Fig. 2A, upper panels) . A similar pattern of microglial activation was observed when we compared cognitive slow and cognitive fast decliner patients Follow-up hippocampal volumes available for n = 35 patients with Alzheimer's disease. *P-value for DPA-1 SUVr comparisons between controls and Alzheimer's disease patients with TSPO genotype as covariate. **P-value for DPA-1 SUVr comparisons between slow and fast decliners (age, TSPO genotype and baseline MMSE as covariates). AD = Alzheimer's disease; co-FD/SD = cognitive fast/slow decliner; fn-FD/SD = functional fast/slow decliner; HAB = high affinity binder; HV = hippocampal volume; MAB = mixed affinity binder.
(P 5 0.001, uncorrected; with age, TSPO and MMSE as covariates) ( Fig. 2A, lower panels) .
Correlations between DPA-1 binding and functional, cognitive and MRI biomarkers outcomes
In the whole group of patients with Alzheimer's disease, we found a negative correlation between DPA-1 binding in the frontal regions and the percentage of increase of the CDRSum of Boxes (SOB) (r = À0.27, P = 0.03; with age, TSPO and MMSE as covariates). Similarly, we found a negative correlation between global cortical DPA-1 binding and the percentage of decrease of the MMSE score (r = À0.28 P = 0.028 for the GCI; with age, TSPO genotype and initial MMSE as covariates). These results suggest that the higher the DPA-1 binding, the lower the functional and cognitive declines. Considering the prodromal Alzheimer's disease group separately, a significant negative correlation was observed with the percentage of MMSE decline (P 5 0.05), but not with the CDR-SOB change.
We also correlated DPA-1 binding with the evolution over time of composite scores reflecting different cognitive domains (long-term memory, short-term memory, instrumental functions, executive functions) in the mild cognitive impairment subjects of the predictive cohort (as patients with mild cognitive impairment were more numerous, and because we had more missing longitudinal neuropsychological data in demented patients, leading to floor effect). We found significant negative correlations between DPA-1 binding in the frontal and anterior cingulate regions and the decline of the composite scores reflecting long-term memory [sum of total recall in the Free and Cued Selective Reminding Test (FCSRT) and temporo-spatial orientation, r = À0.31, P = 0.04 for the frontal region and r = À0.37, P = 0.01 for the anterior cingulate region], and short-term memory (sum of encoding score in the FCSRT and digit spans, r = À0.34, P = 0.029 for the frontal region and r = À0.44, P = 0.006 for the anterior cingulate region). We found no significant correlation with the composite scores reflecting instrumental and executive functions.
Voxel-wise analysis confirms these results, showing negative correlations between DPA-1 binding and MMSE score decrease in frontal and parieto-occipital cortical areas (Fig. 2B, upper panels) .
Progression of hippocampal atrophy was used as a MRI biomarker of Alzheimer's disease progression. The percentage of decrease of hippocampal volume was negatively correlated with the DPA-1 uptake. Highest correlations were found between the left hippocampus atrophy rate and the frontotemporal DPA-1 uptake in prodromal patients with Alzheimer's disease. These data suggest that higher DPA-1 uptake was associated with lower loss of hippocampal volume. Voxel-wise analysis confirmed this correlation in the same cortical areas (Fig. 2B, lower panels) . There was no significant correlation between DPA-1 uptake and the percentage of decrease of cortical grey matter volume.
PiB cortical binding and Alzheimer's disease progression
We did not find any significant results when similar analyses as described above were carried out with using 11 C-PiB binding (no difference of PiB binding between slow and fast decliners as defined either by CDR or MMSE scores changes; no correlation between PiB binding and functional, cognitive or MRI outcomes). Thus, 11 C-PiB (A) Voxel-wise comparisons between slow and fast decliners. (i) Comparison of DPA-1 binding at baseline between functional slow decliners (fn-SD) and functional fast decliners (fn-FD) in the whole Alzheimer's disease population (n = 52, left) and in the prodromal Alzheimer's disease population (n = 33, right). (ii) Comparison of DPA-1 binding at baseline between cognitive slow decliners (co-SD) and cognitive fast decliners (co-FD) in the whole Alzheimer's disease population (n = 49, left) and in the prodromal Alzheimer's disease population (n = 33, right). **P 5 0.001 uncorrected with age, TSPO genotype and initial MMSE as covariates. (B) Correlations between DPA-1 binding and functional, cognitive or MRI biomarkers outcomes using voxel-wise analysis. (i) Correlations between DPA-1 binding and the MMSE change (% of progression), in the whole Alzheimer's disease group (n = 49, left) and in the prodromal Alzheimer's disease group (n = 33, right). (ii) Correlations between DPA-1 binding and the left hippocampal volume change, in the whole Alzheimer's disease group (n = 36, left) and in the prodromal Alzheimer's disease group (n = 26, right). *P 5 0.05 with age, TSPO genotype and initial MMSE as covariates. AD = Alzheimer's disease; HV = hippocampal volume.
binding was not significantly associated with the rate of clinical progression. As previously published, PiB cortical binding correlated with DPA-1 binding (r = 0.5, P = 0.03).
DPA-PET longitudinal analysis Population description
All of the following results were obtained without including the low affinity binders. Patients (n = 21) and controls (n = 13) did not differ with regards to age and educational level. The mean loss in MMSE score after 2 years was 5 points in prodromal patients with Alzheimer's disease, 7.1 points in demented patients with Alzheimer's disease and 0.03 points in controls. The mean interval between both PET scans was 1.6 years in prodromal patients with Alzheimer's disease, 1.4 years in demented patients with Alzheimer's disease and 2.2 years in controls. Detailed neuropsychological data of the population are summarized in Supplementary Table 4 . We also verified that DPA-1 binding in the patients who performed DPA-2 was not significantly different from that of those who did not (DPA-1 GCI = 1.37 AE 0.17 in the 21 patients who had both DPA-1 and DPA-2, and DPA-1 GCI = 1.36 AE 0.2 in the 31 patients who did not perform DPA-2).
Methodological considerations Cerebellar grey matter as a pseudo-reference region
We verified that cerebellar grey matter 18 F-DPA-714 uptake (i) did not differ between patients and controls neither in the first (DPA-1) nor in the second (DPA-2) PET scan; (ii) remained stable individually between DPA-1 and DPA-2 in both patients with Alzheimer's disease (P = 0.1) and controls (P = 0.6), without any difference between groups ( Supplementary Fig. 1) ; and (iii) was not correlated with MMSE score, age, APOE genotype and cortical volume measured by MRI. These results provide additional arguments to those previously published for using the cerebellar grey matter as a pseudo-reference region for quantifying 18 F-DPA-714 binding.
Quantification of longitudinal changes in 18 F-DPA-714 binding
Changes in DPA binding were expressed as an annualized percentage. Because this supposes a linear progression over time, we verified for all analyses that results were not modified when using the global percentage of DPA binding variation, while including the delay between both DPA-PET scans as a covariate.
Comparisons of DPA-1, DPA-2 and DPA binding progression between controls and patients with Alzheimer's disease
Volume of interest analysis
As shown for DPA-1, DPA-2 binding was higher in patients with Alzheimer's disease than in controls in all volumes of interest, especially at the prodromal stage (P 5 0.01) (Supplementary Table 5 ). In the control group,
18
F-DPA-714 binding was stable with time (4.2 AE 4.3% variation per year for the GCI) (Fig. 3A) . In contrast, 18 F-DPA-714 binding significantly increased over time in the Alzheimer's disease group as compared to controls (13.2% per year for the GCI) (P = 0.02), especially at the prodromal stage (15.1% per year versus 8.3% per year at the dementia stage). Individual analysis showed heterogeneous 18 F-DPA-714 binding progression profiles among patients with Alzheimer's disease (Fig. 3B and C) . Voxel-wise analysis DPA-1 and DPA-2 binding were higher in patients with Alzheimer's disease than in controls, especially at the prodromal stage in temporo-parietal regions (P 5 0.001, uncorrected) (Fig. 4A and B) . The annual progression of 18 F-DPA-714 binding was higher in patients with Alzheimer's disease than in controls in fronto-parietal regions (P 5 0.01, uncorrected) (Fig. 4C) .
Correlation between DPA binding progression and functional, cognitive and MRI biomarker outcome
To avoid any confounding bias, age, TSPO binding status and initial MMSE score were defined as covariates for all correlation analyses (either by volume of interest or voxelwise method). We found positive correlations between the increase in 18 F-DPA-714 binding and the annualized percentage of CDR-SOB increase in all volumes of interest, both in the whole group and in prodromal patients with Alzheimer's disease (Supplementary Table 6 ). These data suggest that the increase in 18 F-DPA-714 binding is associated with functional decline over time even at the prodromal stage. Voxel-wise analysis confirmed these results, showing significant correlations in frontal and parieto-temporal regions (Fig. 5A) .
We also found a significant positive correlation between the annualized percentage of increase in DPA binding and the decrease of MMSE score over 2 years, especially in the frontal regions (Supplementary Table 6 ), confirmed by the voxel-wise analysis (Fig. 5B) . These results suggest that progression of 18 F-DPA-714 binding is associated with cognitive decline over time.
Finally, we found significant positive correlations between the annualized percentage of increase in DPA binding and the decrease in left hippocampal volume, in frontal and parieto-temporal cortex over 2 years (Supplementary Table 6 ). This finding was replicated by the voxel-wise analysis (Fig. 5C ).
Correlations between PiB-PET at baseline and DPA binding progression or clinical Alzheimer's disease outcomes
We found no correlation between initial 11 C-PiB binding and either the percentage of DPA binding progression, CDR-SOB progression, changes in MMSE score or the decrease of hippocampal volume over 2 years.
Relationships between DPA-1 binding, DPA binding progression and clinical decline
We found a significant negative correlation between the DPA-1 uptake and the DPA binding progression (r = À0.64, P = 0.002 for the GCI with age, TSPO genotype and initial MMSE score as covariates), suggesting that patients with the highest DPA-1 binding are those who tend to have the lowest increase in DPA binding over time (Fig. 3D) . Interestingly, unlike the extent of initial DPA-1 binding, its longitudinal increase is associated with higher cognitive and functional decline (Fig. 5) as well as faster hippocampal atrophy. This dynamic pattern is observed in both prodromal and demented stages of Alzheimer's disease, even if the statistical significance was stronger in prodromal Alzheimer's disease. Of note, results remained similar when we included age, disease duration, initial MMSE score or initial CDR score as covariates.
Amyloidosis positive controls
Among six amyloidosis positive controls, who were also analysed, including two low affinity binders, only one developed memory cognitive decline during the 2-year follow-up period. The annualized percentages of increase in 18 F-DPA-714 binding in these six amyloidosis-positive controls were + 24.66%, À4.27%, À10.35%, À1.22%, À8.07% and + 17.58%, the two latter percentages corresponding to the low affinity binders. Of note, the only amyloidosis-positive control who developed memory impairment during the follow-up period was a low affinity binder and had both a relatively low DPA-1 GCI of 1.10, and a relatively high annualized percentage of increase in 
Discussion
This study provides new insights into the temporal relationships between microglial activation as measured by 18 F-DPA-714 binding and Alzheimer's disease clinical progression. First, we found in a large cohort of 52 patients with Alzheimer's disease that higher initial 18 F-DPA-714 binding is associated with better clinical prognosis after a 2-year follow-up. Second, the longitudinal DPA-PET study showed that the subsequent increase in 18 F-DPA-714 binding observed in patients with Alzheimer's disease (as compared with controls) was linked to Alzheimer's disease worsening. Finally, patients with lowest initial 18 F-DPA-714 binding had the greatest subsequent increase of microglial activation and unfavourable clinical evolution, while patients with highest initial 18 F-DPA-714 binding had the lowest subsequent increase of microglial activation and more favourable clinical evolution, independently of the initial cortical amyloid load. Altogether, these results support the hypothesis that two distinct dynamic profiles of microglial activation differentially impact on disease progression in patients with Alzheimer's disease, being either beneficial or detrimental, and may vary depending on patients rather than disease stages. Compared with previous works using TSPO PET imaging in Alzheimer's disease, one of the strengths of the current study is the larger sample of subjects (Alzheimer's disease and controls) and the choice of very strict inclusion criteria. In addition to positivity for Alzheimer's disease pathophysiological markers (PiB-PET and CSF biomarkers), we excluded all subjects with known medical events that could influence TSPO binding, such as history of inflammatory diseases and suspicion of alcohol abuse. No change in Alzheimer's disease treatment during the follow-up could explain the difference in clinical progression. In addition, we used a high sensitivity PET scanner (HRRT) together with 18 F-DPA-714, a second generation TSPO tracer, which provides better sensitivity than 11 C-PK11195 for evaluating increased TSPO expression (Chauveau et al., 2009; Yokokura et al., 2017) , and for which mixed affinity and high affinity binders can be pooled more easily than when using 11 C-PBR28, of known much higher affinity ratio between high affinity and low affinity binders (Owen et al., 2011; Hamelin et al., 2016) . Furthermore, TSPO genotype was added as a covariate in all statistical analyses and low affinity binders were excluded from all analyses.
The advantage of having a large cohort is counterbalanced by the lack of arterial blood samples, which may be a limitation to fully quantify the DPA-714 binding. The SUVr method assumes no difference in cerebellar binding at baseline and follow-up. While we observed the stability of cerebellar 18 F-DPA-714 binding over time in patients with Alzheimer's disease and controls, in congruence with previous works using 11 C-PBR28 radioligand, it has not actually been validated using full quantification of DPA-714 data (Lyoo et al., 2015; Kreisl et al., 2016) .
Previous transversal studies using TSPO PET imaging reported controversial findings regarding the protective or deleterious impact of microglial activation in Alzheimer's disease. Some studies showed that 11 C-PK11195 binding correlated with clinical severity, cortical volume atrophy and fluorodeoxyglucose (FDG) hypometabolism, suggesting a toxic effect of microglial activation (Cagnin et al., 2001; Edison et al., 2008; Yokokura et al., 2011) . Conversely, other reports showed no correlation with cognitive scores regardless of whether patients with mild cognitive impairment progressed to dementia or remained clinically stable (Schuitemaker et al., 2013) . Using second generation TSPO tracers, one study suggested that 11 C-PBR28 uptake correlated with cortical volume loss and decrease in several cognitive performances (Lyoo et al., 2015) . In contrast, we previously showed that 18 F-DPA-714 binding correlated positively with MMSE scores and grey matter volume, especially at the prodromal stage, suggesting a protective role of microglial activation (Hamelin et al., 2016) .
Only three longitudinal studies aimed at understanding TSPO binding progression have been reported in Alzheimer's disease so far, which used different radioligands and different quantification methods. Two of them used 11 C(R)-PK11195 tracer and a cluster-based approach for defining the reference region (Fan et al., 2015b (Fan et al., , 2017 . After a 16-month follow-up period, voxel-wise analysis suggested that the increase in microglial activation in patients with Alzheimer's disease (n = 8, MMSE = 21/30) was positively correlated with amyloid deposition and inversely correlated with regional cerebral metabolic rate (Fan et al., 2015b) . However, the small number of patients with Alzheimer's disease, the negativity of amyloid imaging in one of them (calling into question Alzheimer's disease diagnosis) and the lack of longitudinal follow-up of healthy controls limited the interpretation of these data. The same group reported findings in eight subjects with mild cognitive impairment (MMSE = 27.6/30) with different amyloid status, four of eight being amyloid-negative based on PiB-PET imaging (Fan et al., 2017) . The authors described opposite results as compared to those observed in their patients with Alzheimer's disease, with a longitudinal reduction in microglial activation associated with a marginal increase in amyloid load over 14 months. Fan et al. thus proposed the existence of two peaks of microglial activation in the course of Alzheimer's disease, with an early protective peak and a late pro-inflammatory deleterious peak. However, the very small number of mild cognitive impairment due to patients with Alzheimer's disease analysed in this study (only four) raises question about the robustness of such a model. The third longitudinal PET study used 11 C-PBR28 and cerebellum as a pseudo-reference region for quantifying TSPO binding in 14 amyloid-positive patients with Alzheimer's disease at different disease stages (MMSE ranging from 14 to 30; n = 9 patients with CDR = 0.5, n = 5 patients with CDR = 1) and eight controls (Kreisl et al., 2016 ).
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C-PBR28 binding increased in temporo-parietal regions from 3.9% to 6.3% per year in patients versus 0.5% to 1% per year in controls. The increase in TSPO binding correlated with functional worsening on CDR-SOB and with reduced cortical volume. The small number of slow and fast decliners defined by changes in the CDR score (n = 5 and n = 9, respectively) did not allow investigating the binding progression within the prodromal Alzheimer's disease subgroups separately.
Our results are in accordance with Kreisl et al. (2016) , as we found an increase in 18 F-DPA-714 binding over 24 months in patients with Alzheimer's disease as compared with controls (13.2% per year versus 4.2%), both at the prodromal (15.8%) and at the demented stages (8.3%). The positive correlations between the increase in DPA binding and the increase in CDR-SOB scores, MMSE score decrease and rate of hippocampal atrophy suggested a detrimental effect on clinical Alzheimer's disease progression of the subsequent increase in microglial activation, which was not influenced by the initial fibrillar amyloid load. Determining whether such a profile is similar in prodromal and demented stages of Alzheimer's disease remains difficult. Indeed, one limitation of our work is inherent to clinical PET longitudinal studies, as the second PET examination could not be performed in patients at severe dementia stage for obvious ethical reasons. Consequently, the number of patients at the prodromal stage (n = 15) was higher than that of patients at the demented stage (n = 6), precluding sufficiently powerful statistical analyses in the demented subgroup. A larger number of subjects would be necessary to draw precise conclusions.
This deleterious effect of an increasing microglial activation may appear inconsistent with our findings from the DPA-PET predictive analysis, which evidenced a protective effect on Alzheimer's disease progression of higher initial 18 F-DPA-714 binding, confirming our previous studies (Hamelin et al., 2016) . Here we used both functional (CDR score changes) and cognitive (MMSE score decline) outcome measures for defining slow and fast decliners. In addition, we assessed correlations between 18 F-DPA-714 binding and clinical and MRI outcome scores by both volume of interest and voxel-wise methods. Importantly, 18 F-DPA-714 binding at baseline as well as the subsequent increase in 18 F-DPA-714 binding were highly heterogeneous among patients with Alzheimer's disease. Interestingly, patients with the highest initial 18 F-DPA-714 binding display the lowest subsequent increase in 18 F-DPA-714 binding over time, and better prognosis. Conversely, patients with the lowest initial 18 F-DPA-714 binding show a higher subsequent increase in 18 F-DPA-714 binding and a worst prognosis. We must nevertheless acknowledge that in patients with high DPA-1, the course of microglial activation before inclusion in the study remains to be explored.
The follow-up of amyloidosis-positive controls was poorly informative, as the only subject who developed memory impairment during the follow-up period was a low affinity binder. The others remained clinically stable over time and exhibited heterogeneous 18 F-DPA-714 binding progressions. One of the limitations of this study is the low number of subjects in this subgroup and the too short follow-up duration of these patients. Following-up these subjects for a longer period will be highly informative for deciphering the role of microglial activation in preclinical Alzheimer's disease.
The concept of diverse functional phenotypes of immune cells, ranging from pro-inflammatory to immunosuppressive, has been expended to microglia (Tang and Le, 2016) . Importantly, the use of the traditional 'M1/M2 paradigm' of activation status is now considered as oversimplified, and functional differentiation patterns of activated microglia extend much beyond the classical proinflammatory M1-like and neuroprotective M2-like phenotypes, rather spanning a full spectrum of activation patterns (Heneka et al., 2014) . The balance of pro-inflammatory and neuroprotective microglial activation is highly complex, especially in Alzheimer's disease, in which microglia may exhibit mixed activation phenotypes. In this line, a recent study on 299 human brains evidenced an alteration of microglial immunophenotypes in association with ageing and the development of Alzheimer's disease dementia, highlighting the complexity and diversity of microglial responses (Minett et al., 2016) . Up to now, no PET tracer has been able to distinguish between different microglial subtypes or to capture the transition between such different activation states (Vivash and O'Brien, 2016 ).
Beyond the current classical model of neuroinflammation, proposing a homogeneous early protective effect that subsequently turns into a later detrimental effect, our data rather suggest a more complex model based on both distinct patterns and dynamics of microglial activation signatures among patients with Alzheimer's disease, which differently impact on disease progression and contribute to shape diverse clinical evolution profiles. Considering the positive correlation between DPA-1 and PiB binding, the protective microglial signature may reflect an interaction with misfolded deposited proteins and removal of neurotoxic aggregates, especially for fibrillar amyloid deposition (Fan et al., 2015b; Parbo et al., 2017) . The detrimental microglial signature could reflect an interplay with neuronal injury processes, possibly independently of amyloid pathology when considering the absence of correlation between PiB uptake and the increase in 18 F-DPA-714 binding. Protective or deleterious microglial signatures are both observed at the prodromal stage, and mostly do not seem related to the severity of the disease. Our data rather suggest that the relative extent and dynamics of beneficial and detrimental microglial activation signatures may vary among patients, thus translating into different clinical evolution profiles. Identifying the factors modulating this balance between such different signatures will be of major importance for both prognostic and therapeutic purposes. In this line, our previous studies in a mouse model of Alzheimer's disease-like pathology suggested that peripheral modulation of a given T cell population could impact on the rate of disease progression at least partially by modulating microglial responses (Dansokho et al., 2016) .
Hence, different subtypes of patients with Alzheimer's disease may benefit from different treatment protocols and/or innovative therapeutic approaches targeting inflammatory and immune responses. PET imaging using 18 F-DPA-714 appears as a highly valuable tool for identifying target populations and assessing drug efficacy in such studies, even if we cannot exclude that some other biological parameters could also influence Alzheimer's disease progression.
